Dr Nikola Kotur is a molecular biologist whose research focuses on pharmacogenomics, nutrigenetics, and genetic factors underlying complex diseases. He obtained his degree in Molecular Biology and Physiology in 2009 from the Faculty of Biology, University of Belgrade, and defended his PhD thesis titled “Pharmacogenetics of 6-mercaptopurine and methotrexate in childhood acute lymphoblastic leukemia” in 2015 at the same faculty. In 2021, he completed the course “Bioinformatics for Biologists” at the Faculty of Computing, Union University in Belgrade. Since 2011, he has been employed at the IMGGE, in the Group for Molecular Biomedicine. Throughout his career, he has worked on the pharmacogenetics of anti-inflammatory and antileukemic drugs in acute lymphoblastic leukemia and inflammatory diseases. He has participated in numerous national and international projects, including Horizon Europe projects, serving as a work package leader. Through the PharmGenHub project, he contributed to comprehensive pharmacogenetic profiling of Western Balkan populations, while within the InnoThyroGen project, he studies the pharmacogenomics of thyroid disease therapy as well as genetic and non-genetic risk factors of these diseases with the aim of developing risk assessment models. He leads the working group of the COST Action INFLAMomx, which aims to systematize multi-omic protocols for complex disease analysis. In his research, he applies advanced statistical and bioinformatics methods and has served as a member of the organizing committee of the Belgrade Bioinformatics Conference (2018, 2024) as well as a lecturer or organizer of more than fifteen summer schools, workshops, and courses dedicated to the application of bioinformatics and pharmacogenetics in biomedical research.